You are here: Industry Insights > IPF

News List

BioMed X Reaches Milestone in Respiratory Disease Research Collaboration with Boehringer Ingelheim b3cnewswire
December 04, 2019
BioMed X announced the successful completion of their first joint research project with Boehringer Ingelheim in the fields of chronic obstructive pulmonary disease (COPD) ...
Risk for Developing Idiopathic Pulmonary Fibrosis Up in IBD drugs
September 26, 2019
Patients with inflammatory bowel disease (IBD), especially male patients, have an increased risk for development of idiopathic pulmonary fibrosis (IPF) ...
Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline contractpharma
July 24, 2019
Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877.
Ofev Study Results Released of Fibrotic Progression in Patients with IPF americanpharmaceuticacreview
November 13, 2017
Boehringer Ingelheim announced results from a descriptive Phase IIIb lung imaging study providing evidence for the first time that Ofev (nintedanib) slowed the fibrotic process versus placebo in people with idiopathic pulmonary fibrosis (IPF).
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds o worldpharmanews
September 20, 2017
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost.
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonar worldpharmanews
May 27, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International Conference.

Previous page 1 2 Next page